Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

• Status: RECRUITING
• Trial end date: 2028-10-01

Summary

To evaluate progression of metastatic renal cell carcinoma from the initiation of PULSAR radiotherapy in combination with IMSA101 injectable onward.

• Phase: PHASE2

Details

• Lead Sponsor: University of Texas Southwestern Medical Center